2024-515964-30-00招募中2 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 33
- 试验地点
- 6
- 主要终点
- Not applicable
研究概览
简要总结
• Allow patients to continue or start AP01 therapy for the treatment of ILD and IPF until applicable regulatory approval or until the study is terminated • To evaluate safety outcomes of patients while on AP01 therapy
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Prior participant in an Avalyn AP01 study, excluding normal healthy volunteers OR
- •Patients with no other treatment options with ILDs, including but not limited to IPF, fibrosing phenotype ILD, pulmonary involvement of scleroderma, rheumatoid lung and silicosis. Prior Sponsor approval of non-Avalyn study rollover patients is required.
- •Diagnosed chronic progressive fibrotic ILD, including IPF, without treatment alternatives such as: a. Not eligible for oral pirfenidone and nintedanib due to national formulary restrictions or lack of applicable regulatory approval b. Intolerant to oral pirfenidone and nintedanib, if previously offered c. Not eligible for an ongoing clinical study of AP01 other than this study
- •Age greater than 18 years at Screening
- •Able to understand and sign, prior to study entry, a written informed consent form (ICF) consistent with International Council on Harmonisation Guideline for Good Clinical Practice (ICH-GCP) and local laws
- •Able to understand the importance of adherence to study treatment and the study protocol and willing to follow all study requirements, including the concomitant medication restrictions, throughout the study
- •Females of childbearing potential (FOCBP) must use an effective contraceptive method during the clinical study and 30 days after the last dose of AP01 as described in Section 7.3.6, Pregnancy Testing.
排除标准
- •Disease-Related Exclusions
- •Significant clinical worsening of ILD/IPF for AP01 naïve patients between Screening and Day 1, in the opinion of the Investigator
- •Participation in a clinical study with administration of an investigational drug product within the previous 30 days, or five half-lives of the previously administered investigational product (IP) (AP01 naïve patients only)
- •Hypersensitivity to the active substance or to any of the excipients of pirfenidone
- •Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study, in the opinion of the Investigator
- •History of acute IPF exacerbation requiring hospitalization in the last 30 days
- •Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis, urinary tract infection, or cellulitis
- •Medical Exclusions
- •Females with a positive pregnancy test at Screening (AP01 naïve patients) or Baseline (Rollover patients from previous study) or are currently breastfeeding
- •Any history of malignancy likely to result in significant disability or likely to require significant medical or surgical intervention within the next 6 months. This does not include minor surgical procedures for localized cancer (e.g., basal cell carcinoma)
- •Any condition other than ILD/IPF that, in the opinion of the Investigator, is likely to result in the death of the patient within the next 6 months
- •History of severe hepatic impairment, end-stage liver disease, or AST or ALT greater than 5 times the upper limit of normal at Screening (AP01 naïve patients)
- •History of end-stage renal disease requiring dialysis
结局指标
主要结局
Not applicable
Not applicable
次要结局
- Treatment-emergent adverse events (AEs)
- Treatment-emergent deaths
研究者
Craig S. Conoscenti, MD
Scientific
Avalyn Pharma Inc.
研究点 (6)
Loading locations...
相似试验
招募中
2 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisInterstitial Lung Disease (ILD) which cause inflammation and scarring (firbrosis) of the lungs10038716NL-OMON52355Avalyn Pharma, Inc4
进行中（未招募）
1 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisInterstitial Lung Diseases (ILD), including but not limited to idiopathic pulmonary fibrosis (IPF)MedDRA version: 21.1Level: PTClassification code 10022611Term: Interstitial lung diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-005103-39-CZAvalyn Pharma, Inc.100
进行中（未招募）
1 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisEUCTR2020-005103-39-PLAvalyn Pharma, Inc.100
进行中（未招募）
2 期
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary FibrosisProgressive, fibrosing interstitial lung diseaseIdiopathic Pulmonary Fibrosis (IPF)Respiratory - Other respiratory disorders / diseasesACTRN12621000170820Avalyn Pharma Pty Ltd100
进行中（未招募）
1 期
CLINICAL TRIAL TO EVALUATE THE EFFICIENCY OF PYRPHENIDONE FOR THE REDUCTION OF PULMONARY INFLAMMATION IN PATIENTS WITH SILICOSIS AND PROGRESSIVE MASSIVE FIBROSIS.progressive massive fibrosisMedDRA version: 20.0Level: PTClassification code 10040678Term: SilicosisSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: PTClassification code 10036805Term: Progressive massive fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-002701-94-ESFundación para la Gestión de la Investigación Biomédica de Cádiz18